Orphan revise continues to move

WASHINGTON - The House Energy and Commerce Committee reported out Orphan Drug legislation (HR 4160) that includes "safe harbor" provisions guaranteeing seven years of market exclusivity for orphan drugs with revenues below a threshold.

The House bill